

# Jan Libiger

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5436983/jan-libiger-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

33 papers	1,920 citations	18 h-index	33 g-index
33 ext. papers	2,161 ext. citations	6.3 avg, IF	3.61 L-index

#	Paper	IF	Citations
33	A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale. <i>European Neuropsychopharmacology</i> , <b>2019</b> , 29, 947-959	1.2	36
32	Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. <i>Lancet Psychiatry</i> , <b>2018</b> , 5, 797-807	23.3	100
31	Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST). <i>Schizophrenia Research</i> , <b>2016</b> , 172, 145-51	3.6	23
30	Gender differences in the treatment of first-episode schizophrenia: Results from the European First Episode Schizophrenia Trial. <i>Schizophrenia Research</i> , <b>2015</b> , 169, 303-307	3.6	18
29	Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. <i>European Neuropsychopharmacology</i> , <b>2013</b> , 23, 196-204	1.2	99
28	Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study. <i>Schizophrenia Research</i> , <b>2013</b> , 147, 132-139	3.6	36
27	Differences in onset of disease and severity of psychopathology between toxoplasmosis-related and toxoplasmosis-unrelated schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , <b>2013</b> , 127, 227-38	6.5	42
26	Insight and hostility as predictors and correlates of nonadherence in the European First Episode Schizophrenia Trial. <i>Journal of Clinical Psychopharmacology</i> , <b>2013</b> , 33, 258-61	1.7	11
25	Different serine and glycine metabolism in patients with schizophrenia receiving clozapine. <i>Journal of Psychiatric Research</i> , <b>2012</b> , 46, 811-8	5.2	8
24	The interrelation of needs and quality of life in first-episode schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2012</b> , 262, 207-16	5.1	13
23	Unmet needs in patients with first-episode schizophrenia: a longitudinal perspective. <i>Psychological Medicine</i> , <b>2012</b> , 42, 1461-73	6.9	21
22	Attitudes of patients with schizophrenia and depression to psychiatric research: a study in seven European countries. <i>Social Psychiatry and Psychiatric Epidemiology</i> , <b>2011</b> , 46, 159-65	4.5	11
21	Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). <i>Journal of Clinical Psychiatry</i> , <b>2011</b> , 72, 955-61	4.6	37
20	Glycine serum level in schizophrenia: relation to negative symptoms. <i>Psychiatry Research</i> , <b>2010</b> , 176, 103-8	9.9	28
19	Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). <i>American Journal of Psychiatry</i> , <b>2009</b> , 166, 675-82	11.9	249
18	Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). <i>Schizophrenia Research</i> , <b>2009</b> , 115, 97-103	3.6	92
17	Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study. <i>Schizophrenia Research</i> , <b>2009</b> , 115, 104-14	3.6	79

16	Subjective well-being with antipsychotic treatment. <i>Acta Neuropsychiatrica</i> , <b>2009</b> , 21 Suppl 2, 65	3.9	
15	Visual mismatch negativity among patients with schizophrenia. <i>Schizophrenia Research</i> , <b>2008</b> , 102, 320-8	3.6	41
14	Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. <i>Lancet, The</i> , <b>2008</b> , 371, 1085-97	4.0	823
13	Visual information processing in recently abstaining methamphetamine-dependent individuals: evoked potentials study. <i>Documenta Ophthalmologica</i> , <b>2008</b> , 117, 245-55	2.2	6
12	D-serine serum levels in patients with schizophrenia: relation to psychopathology and comparison to healthy subjects. <i>Neuroendocrinology Letters</i> , <b>2008</b> , 29, 485-92	0.3	8
11	Psychiatry benefits from psychopathology and diagnosis in shaping clinical management. <i>Current Opinion in Psychiatry</i> , <b>2007</b> , 20, 202-3	4.9	0
10	Clinical and demographic characteristics of psychiatric patients seropositive for <i>Borrelia burgdorferi</i> . <i>European Psychiatry</i> , <b>2006</b> , 21, 118-22	6	9
9	Comorbidity of parkinsonism and schizophrenia in a patient treated with clozapine. <i>European Psychiatry</i> , <b>2003</b> , 18, 258-9	6	11
8	Higher prevalence of antibodies to <i>Borrelia burgdorferi</i> in psychiatric patients than in healthy subjects. <i>American Journal of Psychiatry</i> , <b>2002</b> , 159, 297-301	11.9	21
7	Antiepileptic drugs in schizophrenia: a review. <i>European Psychiatry</i> , <b>2002</b> , 17, 371-8	6	57
6	Treatment in The Early Stages of Psychosis <b>2001</b> , 181-195		
5	Effects of haloperidol treatment on prolactin response to D-fenfluramine challenge in acute schizophrenia. <i>Psychopharmacology</i> , <b>1999</b> , 141, 322-5	4.7	8
4	Prolactin response to D-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia. <i>Schizophrenia Research</i> , <b>1998</b> , 30, 91-9	3.6	23
3	Rhythmic finger-tapping task and fast segmentation of neural processing in schizophrenics. <i>Biological Psychiatry</i> , <b>1996</b> , 40, 1301-4	7.9	7
2	Does the change of psychopathology during the placebo period predict the response to subsequent treatment with active medication. <i>Psychiatry Research</i> , <b>1994</b> , 52, 107-14	9.9	2
1	Drug induced dementia. <i>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</i> , <b>1980</b> , 4, 561-7		1